REQUEST A DEMO
Total
USD $0.00
Search more companies

Prestige Biopharma (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Prestige Biopharma Profile Updated: December 11, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

Prestige Biopharma is an enterprise in South Korea, with the main office in Singapore. It operates in the Research and Development in Nanotechnology industry. It was established on July 13, 2015. 67 (2025) employees currently work for Prestige Biopharma. There was a net sales revenue increase of 4.05% reported in Prestige Biopharma’s latest financial highlights for Q12026. Over the same period, its total assets grew by 0.57%. The net profit margin of Prestige Biopharma decreased by 390.73% in 2026.

Headquarters
21 Biopolis Road, 04-24/28 Nucleos South Building
Singapore; Singapore;

Contact Details: Purchase the Prestige Biopharma report to view the information.

Website: http://www.prestigebiopharma.com

Basic Information
Total Employees:
Purchase the Prestige Biopharma report to view the information.
Outstanding Shares:
Purchase the Prestige Biopharma report to view the information.
Registered Capital:
Purchase the Prestige Biopharma report to view the information.
Financial Auditors:
Purchase the Prestige Biopharma report to view the information.
Incorporation Date:
July 13, 2015
Key Executives
Purchase this report to view the information.
Chairman
Subsidiaries
프레스티지바이오파마코리아(주)
Company Performance
Financial values in the chart are available after Prestige Biopharma report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
4.05%
Total Operating Revenue
10.92%
Operating Profit
-56.69%
EBITDA
-56.04%
Net Profit/Loss for the Period
-87.72%
Total Assets
0.57%
Total Equity
3.05%
Operating Profit Margin
-350.96%
Net Profit Margin
-390.73%
Return on Equity (ROE)
-1.96%
Debt / Equity
2.8%
Quick Ratio
-0.34%
Cash Ratio
-0.31%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?